Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Hims vs Options Medical Weight Loss

Hims and Options Medical Weight Loss both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
Hims logo

Hims

6.8
★★★☆☆3.4/5

Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC

Visit Hims →
VS
Options Medical Weight Loss logo

Options Medical Weight Loss

6.9
★★★★☆3.5/5

Best for: compounded semaglutide at $199/month

Visit Options Medical Weight Loss →

If you are choosing between Hims and Options Medical Weight Loss, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Options Medical Weight Loss leads our six-part score, 6.9 to 6.8. One of the two has an FDA warning letter on record, covered below.

Hims vs Options Medical Weight Loss price

Hims and Options Medical Weight Loss start at the same figure, $199 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.

Drug by drug: Semaglutide costs the same at both, $199 a month; tirzepatide is cheaper at Hims ($299 a month vs $399 a month).

Medications and formats

Both sell semaglutide and tirzepatide.

On format, Hims prices compounded injections and brand-name pens, while Options Medical Weight Loss prices compounded injections.

If you want the FDA-approved brand rather than a compounded version, Hims is the only one of the two with a brand-name price.

Where each one treats patients

Hims lists 50 states, and Options Medical Weight Loss does not publish where it ships.

Pricing

Hims

StartingCompounded
$199/mo
semaglutide
StartingBrand-name
$299/mo
tirzepatide

Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)

Options Medical Weight Loss

Injectablecompounded injection
$199/mo
semaglutide

Compounded; programs start at $199/mo, HSA/FSA eligible

Injectablecompounded injection
$399/mo
tirzepatide

Compounded; higher tiers $339-$399/mo

What each price covers

Both prices cover the medication itself.

Options Medical Weight Loss' price also covers the clinician visit and shipping, which Hims does not claim.

Hims is silent on shipping and lab work.

Options Medical Weight Loss is silent on lab work and coaching.

Hims

Covered by the monthly price

Medication

In the price

Clinician visits

Charged on top

Shipping

Not stated

Lab work

Not stated

Coaching

Charged on top

Options Medical Weight Loss

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Where each one scores higher

Overall, Options Medical Weight Loss scores 6.9 and Hims 6.8 out of 10.

Hims is stronger on user experience (8.0 vs 7.5), trust & safety (7.0 vs 6.5) and accessibility (10.0 vs 5.0).

Options Medical Weight Loss is stronger on value (4.5 vs 3.0) and support (7.0 vs 3.0).

Effectiveness is within half a point.

How we score

Hims

6.8/10

Overall

Options Medical Weight Loss

6.9/10

Value25%

3.0A
vs
B
4.5

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
7.5

Trust & Safety15%

7.0A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

3.0A
vs
B
7.0

FDA warning letters

The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.

Options Medical Weight Loss has no FDA warning letter on record with us.

Features & Coverage

FeatureHimsOptions Medical Weight Loss
Starting Price$199/mo$199/mo
Features2 features✓8 features
States Available50Not disclosed
Compounded✓ Yes—
Brand Name✓ Yes—
FSA/HSA Accepted—✓ Yes
FDA Warning Letters1 letter✓None

About Hims

Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.

Read our full Hims review →

About Options Medical Weight Loss

Options Medical Weight Loss prices compounded semaglutide starting around $239/month and tirzepatide from $299/month, with NAD+ injections at $199/month; programs start at $199/month and are HSA/FSA eligible. GLP-1 is used as one tool inside a broader metabolic-health plan with provider support and accountability. The brand is LegitScript certified and runs in-person clinics alongside its telehealth program.

Read our full Options Medical Weight Loss review →

Pros & Cons

Hims

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication
  • Serves all 50 states
  • Names 4 pharmacies that fill its prescriptions, which most sellers do not

Watch-outs

  • Not included in the monthly price: clinician visits, coaching
  • The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Options Medical Weight Loss

What we like

  • Semaglutide costs $199 a month, close to the $185 median for compounded semaglutide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping
  • We found no FDA warning letters issued to Options Medical Weight Loss
  • A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake

Watch-outs

  • Tirzepatide costs $399 a month, 60% above the $250 median for compounded tirzepatide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Options Medical Weight Loss

Options Medical Weight Loss wins this one, 6.9 to 6.8, above all for compounded semaglutide at $199/month. Hims fits better if knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC is your priority.

Choose Hims if…

You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.

Choose Options Medical Weight Loss if…

You want compounded semaglutide at $199/month and an opening price near $199 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.1

DudeMeds

Compounded semaglutide at $175/month

7.8

Oak

Semaglutide at $119/month, 37% below the typical price

9.4

Trimi Health

Knowing which pharmacy fills the vial: it names VialsRx

Hims vs Options Medical Weight Loss: FAQ

Neither on the entry price: Hims and Options Medical Weight Loss both start at about $199 a month. The difference is in what the price includes.
Yes, both sell semaglutide and tirzepatide.
Hims lists 50 states; Options Medical Weight Loss does not publish where it ships. Confirm your state before paying.
Both include the medication itself. Only Options Medical Weight Loss includes the clinician visit and shipping.
Hims has an open FDA warning letter from September 9, 2025. Options Medical Weight Loss has none.
No. Neither Hims nor Options Medical Weight Loss pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.